DZ1876A1 - Médicaments pour administration orale. - Google Patents

Médicaments pour administration orale.

Info

Publication number
DZ1876A1
DZ1876A1 DZ950044A DZ950044A DZ1876A1 DZ 1876 A1 DZ1876 A1 DZ 1876A1 DZ 950044 A DZ950044 A DZ 950044A DZ 950044 A DZ950044 A DZ 950044A DZ 1876 A1 DZ1876 A1 DZ 1876A1
Authority
DZ
Algeria
Prior art keywords
medicines
oral administration
oral
administration
Prior art date
Application number
DZ950044A
Other languages
English (en)
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10754044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ1876(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Application granted granted Critical
Publication of DZ1876A1 publication Critical patent/DZ1876A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
DZ950044A 1994-04-23 1995-04-22 Médicaments pour administration orale. DZ1876A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9408117A GB9408117D0 (en) 1994-04-23 1994-04-23 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DZ1876A1 true DZ1876A1 (fr) 2002-02-17

Family

ID=10754044

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ950044A DZ1876A1 (fr) 1994-04-23 1995-04-22 Médicaments pour administration orale.

Country Status (35)

Country Link
US (1) US6051255A (fr)
EP (5) EP0758235B1 (fr)
JP (1) JP3622975B2 (fr)
CN (1) CN1134258C (fr)
AP (2) AP564A (fr)
AT (6) ATE203161T1 (fr)
AU (1) AU684949B2 (fr)
BG (1) BG62842B1 (fr)
BR (1) BR9507502A (fr)
CA (1) CA2188496A1 (fr)
CZ (2) CZ11376U1 (fr)
DE (5) DE69521799T2 (fr)
DK (4) DK1093813T3 (fr)
DZ (1) DZ1876A1 (fr)
ES (4) ES2161288T3 (fr)
FI (1) FI964249A0 (fr)
GB (1) GB9408117D0 (fr)
GR (2) GR3035031T3 (fr)
HK (5) HK1009936A1 (fr)
HU (1) HU228399B1 (fr)
IL (1) IL113433A (fr)
MA (1) MA23528A1 (fr)
MY (1) MY115351A (fr)
NO (1) NO310703B1 (fr)
NZ (1) NZ285080A (fr)
OA (1) OA10377A (fr)
PL (1) PL316966A1 (fr)
PT (4) PT761218E (fr)
RO (1) RO116997B1 (fr)
RU (1) RU2152213C1 (fr)
SA (1) SA95160343B1 (fr)
SI (1) SI0758235T1 (fr)
SK (1) SK282594B6 (fr)
WO (1) WO1995028927A1 (fr)
ZA (1) ZA953236B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DZ2028A1 (fr) * 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
DE69617036T2 (de) * 1995-09-07 2002-07-11 Smithkline Beecham Corp Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung
AT407701B (de) * 1996-08-12 2001-05-25 Biochemie Gmbh Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung
TWI225402B (en) 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
GB9617780D0 (en) 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
AU6496498A (en) * 1997-02-07 1998-08-26 Gist-Brocades B.V. Homogeneous granulated formulations for dose sipping technology
EA002595B1 (ru) * 1997-02-14 2002-06-27 Смитклайн Бичем Лаборатуар Фармасетик Фармацевтический препарат, содержащий амоксициллин и клавуланат, способ его приготовления и гранулят, содержащий амоксициллин и клавуланат
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
AU9540898A (en) * 1997-08-29 1999-03-22 Dsm N.V. Granules free of excipients
CA2307887A1 (fr) 1997-10-31 1999-05-14 Monsanto Company Enrobage de comprimes a l'aide de gomme gellane
CN1209099C (zh) 1999-04-01 2005-07-06 Dsm公司 结晶化附聚物
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
CO5170471A1 (es) * 1999-04-13 2002-06-27 Beecham Pharmaceutical Pte Ltd Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US20040038948A1 (en) * 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
GB9930578D0 (en) * 1999-12-23 2000-02-16 Smithkline Beecham Plc Pharmaceutical formulations
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
AU2001279284A1 (en) * 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US6756057B2 (en) * 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (fr) * 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Nouvelle formulation
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
WO2003066053A1 (fr) * 2002-02-07 2003-08-14 Rutgers, The State University Polymeres antibiotiques
ATE329581T1 (de) * 2002-02-14 2006-07-15 Glaxo Group Ltd Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydr -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet
GB0203528D0 (en) * 2002-02-14 2002-04-03 Glaxo Group Ltd Process and composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
CA2406592C (fr) * 2002-10-04 2003-09-30 Duchesnay Inc. Mode de preparation de formes posologiques pharmaceutiques contenant de multiples principes actifs
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CA2533292C (fr) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation correspondantes
WO2005009364A2 (fr) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation associees
CA2533178C (fr) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Produit antibiotique, son utilisation et sa formulation
WO2005016311A1 (fr) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Pastille robuste
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
DE10341264A1 (de) * 2003-09-04 2005-03-24 Grünenthal GmbH Schmelzformulierte, multipartikuläre orale Darreichungsform
EP1663169A4 (fr) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotique, son utilisation et sa formulation
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
DE602005023965D1 (de) 2004-03-08 2010-11-18 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
KR100638315B1 (ko) * 2004-07-23 2006-10-25 주식회사 대웅제약 다중 필름 코팅된 코어층을 갖는 클라불라네이트 및아목시실린-함유 유핵정
TWI367755B (en) 2005-05-20 2012-07-11 Sankyo Co Film coated product
KR100780553B1 (ko) * 2005-08-18 2007-11-29 한올제약주식회사 메트포르민 서방정 및 그의 제조방법
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CL2008003230A1 (es) * 2007-11-01 2009-11-27 Sanofi Aventis Healthcare Pty Ltd Composicion de recubrimiento de tableta que comprende polimero celulosico, plastificante, edulcorante y composicion de sabor en polvo la que comprende saborizante asociado con portador solido; fluido de recubrimiento de tableta que comprende dicha composicion; tableta farmaceutica; proceso de preparacion de dicha tableta.
CN104666272A (zh) * 2009-09-18 2015-06-03 赛诺菲 稳定性提高的(z)-2-氰基-3-羟基-丁-2-烯酸-(4’-三氟甲基苯基)-酰胺片剂制剂
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
GB1508977A (en) 1974-04-20 1978-04-26 Beecham Group Ltd Beta-lactam antibiotic from streptomyces clavuligerus
US4098897A (en) * 1975-04-14 1978-07-04 Beecham Group Limited Anti bacterial agents
JO984B1 (en) 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
EP0080862B1 (fr) * 1981-12-02 1985-09-25 Beecham Group Plc Préparation pharmaceutique contenant des antibiotiques béta-lactame
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
CO5170471A1 (es) * 1999-04-13 2002-06-27 Beecham Pharmaceutical Pte Ltd Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
EP1330236A2 (fr) * 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Nouvelle formulation

Also Published As

Publication number Publication date
CZ294168B6 (cs) 2004-10-13
EP0758235B1 (fr) 2001-07-18
EP1093813B1 (fr) 2002-10-16
ATE223706T1 (de) 2002-09-15
BG100933A (en) 1997-07-31
HK1050992A1 (zh) 2003-07-18
PT761218E (pt) 2001-03-30
DE69528608D1 (de) 2002-11-21
NO310703B1 (no) 2001-08-20
EP0978276B1 (fr) 2002-09-11
BG62842B1 (bg) 2000-09-29
SA95160343B1 (ar) 2005-05-04
WO1995028927A1 (fr) 1995-11-02
HU228399B1 (en) 2013-03-28
ES2161288T3 (es) 2001-12-01
EP0758235A1 (fr) 1997-02-19
ES2180251T3 (es) 2003-02-01
RU2152213C1 (ru) 2000-07-10
CZ309096A3 (en) 1997-04-16
ATE203161T1 (de) 2001-08-15
MA23528A1 (fr) 1995-12-31
RO116997B1 (ro) 2001-09-28
OA10377A (en) 2001-11-21
HK1021860A1 (en) 2000-07-07
EP0761218B1 (fr) 2000-10-11
BR9507502A (pt) 1997-09-02
DE69521799T2 (de) 2002-06-13
HK1009936A1 (en) 1999-06-11
GR3035031T3 (en) 2001-03-30
EP1093813A3 (fr) 2001-05-30
ZA953236B (en) 1995-12-27
AP9600868A0 (en) 1996-10-31
CZ11376U1 (cs) 2001-07-12
SI0758235T1 (en) 2001-10-31
CA2188496A1 (fr) 1995-11-02
EP0978276A2 (fr) 2000-02-09
DE69528204D1 (de) 2002-10-17
PT978276E (pt) 2003-01-31
SK135496A3 (en) 1997-05-07
SK282594B6 (sk) 2002-10-08
EP1243267A3 (fr) 2002-10-30
HK1027024A1 (en) 2001-01-05
AT5350U1 (de) 2002-06-25
HU9602922D0 (en) 1996-12-30
DK0978276T3 (da) 2003-01-20
AP9500733A0 (en) 1995-04-30
PL316966A1 (en) 1997-03-03
PT1093813E (pt) 2003-02-28
DK0758235T3 (da) 2001-10-29
DE69519093T2 (de) 2001-07-19
DE29522153U1 (de) 2000-04-06
DE69521799D1 (de) 2001-08-23
US6051255A (en) 2000-04-18
AU684949B2 (en) 1998-01-08
GR3036844T3 (en) 2002-01-31
AT5349U1 (de) 2002-06-25
CN1134258C (zh) 2004-01-14
DK1093813T3 (da) 2003-02-17
DE69528204T2 (de) 2003-08-07
FI964249A (fi) 1996-10-22
AU2406895A (en) 1995-11-16
NO964488L (no) 1996-12-17
EP0978276A3 (fr) 2000-04-12
EP1243267A2 (fr) 2002-09-25
HUT76335A (en) 1997-08-28
CN1149829A (zh) 1997-05-14
GB9408117D0 (en) 1994-06-15
MY115351A (en) 2003-05-31
NZ285080A (en) 1998-05-27
IL113433A (en) 2003-06-24
HK1036404A1 (en) 2002-01-04
ES2152485T3 (es) 2001-02-01
DK0761218T3 (da) 2000-12-18
EP0761218A1 (fr) 1997-03-12
AP564A (en) 1996-11-21
DE69519093D1 (de) 2000-11-16
FI964249A0 (fi) 1996-10-22
EP1093813A2 (fr) 2001-04-25
DE69528608T2 (de) 2003-06-26
PT758235E (pt) 2001-10-31
IL113433A0 (en) 1995-07-31
ATE196845T1 (de) 2000-10-15
ES2182754T3 (es) 2003-03-16
ATE226074T1 (de) 2002-11-15
NO964488D0 (no) 1996-10-22
JPH09512027A (ja) 1997-12-02
JP3622975B2 (ja) 2005-02-23

Similar Documents

Publication Publication Date Title
DZ1876A1 (fr) Médicaments pour administration orale.
FI921060A0 (fi) Farmaceutiska aerosolformuleringar.
FI922958A0 (fi) Farmaceutisk sammansaettning.
FI922252A0 (fi) Farmaceutisk sammansaettning.
FI922316A0 (fi) Farmaceutisk sammansaettning.
ITBO910024A1 (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
DE69513671D1 (de) Arzneimittel
DK0742715T3 (da) Orale, væskeformige præparater indeholdende paroxetin-resinat
FI923581A0 (fi) Farmaceutisk kombinationsformation.
NO912799L (no) Foradditiver for droevtyggere.
DE69518331T2 (de) Orale zubereitungen
EE9600118A (et) Uus peroraalne farmatseutiline annusvorm
BR9706897B1 (pt) forma de dosagem farmacêutica.
ITRM940002A0 (it) Composizione orale.
DE68903858T2 (de) Orale mittel fuer wiederkaeuer.
DZ1559A1 (fr) Compositions pharmaceutiques.
NL1006015A1 (nl) Toedieninrichting.
EP0670166A3 (fr) Compositions pharmaceutiques administrables par voie buccale.
TR199501082A2 (tr) Farmasötik formülasyonlar.
DE69432149D1 (de) Orale Zubereitungen
DE69300492T2 (de) Orale Zusammensetzung.
FI921786A0 (fi) Farmaceutisk foerening.
TR199601018A1 (tr) Farmasötik bilesikler.
FI921785A0 (fi) Farmaceutisk foerening.
FI934317A0 (fi) Farmaceutiska sammansaettningar, vilka innehaoller ej-joniska ytaktiva aemnen